All News
Happy Diwali (11.1.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
Iberdomide Efficacy in Cutaneous Lupus
Iberdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).
Read Article
Should They Put Off Hip Replacement Surgery?
The NEJM reports what should be obvious to rheumatologists: that older adults with severe hip osteoarthritis should opt for total hip replacement (THR) over conservative exercise measures as THR yields a clinically important improvement in pain and function.
Read Article
GLP-1 Inhibitor Reduces Knee Osteoarthritis Pain
d
MedPage Today
Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis, a randomized trial showed.
Read Article
Medscape 2024 Medical Student Experience Survey
Medscape has published a survey overview of US Medical Student impressions and experiences, satisfaction, what they think of their education and how prepared are they for the USMLE (boards) and residency.
Read Article
Myelitis Associated With Rheumatologic Dz studied in 41 pts (age 44yrs; 95%women). Dx: SLE (41%), Sjogrens (24%), UCTD (15%), Overlap (12%) w/ APL syndr. Half Dx were AQP4-IgG Ab+ (90% w/ extensive cord lesions), 7% MOGAD Ab+, 44% "double-seronegative" myelitis.… https://t.co/or6vuCZASs https://t.co/UxzSR6yJO5
Dr. John Cush RheumNow ( View Tweet)
Overview of IL-23 inhibition for chronic inflammatory disease (partial read) from Lancet. Started with targeting the p40 subunit shared between IL-12 & IL-23A. Now we have specific inhibitors of the p19 protein of IL-23A. These agents are superior to TNFi in plaque… https://t.co/ud61WLgWs2 https://t.co/fQ7WhLyrsi
Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine effects studied in 30pts (23 RA, 7SLE). Results did not support that HCQ may reduce CV risk - Arterial stiffness was not affected by HCQ, HCQ modestly lowered HbA1c & lipids - yet HCQ has been shown to reduced CV risk in observational studies… https://t.co/n283HwvRm4 https://t.co/lQN342uevy
Dr. John Cush RheumNow ( View Tweet)
SGLT2 Inhibitor Protective Effects in Lupus
Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).
https://t.co/I5ZrA9pXRU https://t.co/8U0ILPbMuN
Dr. John Cush RheumNow ( View Tweet)
Swapping is Better than Cycling in Psoriatic Arthritis
A real-world cohort study suggests that psoriatic arthritis failing to respond to TNF inhibitors (TNFi) may do better if they subsequently swap to an IL-17 inhibitor (IL-17i), rather than cycling to another TNFi.… https://t.co/VREQCx8TfI https://t.co/ylzYPHhedi
Dr. John Cush RheumNow ( View Tweet)
Study of 168 patients with MDA5-positive Dermatomyositis finds that elevated IL-6 (≥ 13.41pg/m), lymphopenia (< 0.5 × 109) older age and high LDH predicted 6-month all-cause mortality in DM https://t.co/eHYrUtvsI9 https://t.co/SAy27Om2zu
Dr. John Cush RheumNow ( View Tweet)
Psoriasis pts w/ Arthralgia referred for Rheum Eval - 1419 referred pts, 8.4% (119) met at risk for PsA criteria, and 29% (35) developed PsA w/in 1yr. Predictors included +FHx PsO, Ultrasound synovitis or enthesopathy findings, & low tender joint count. https://t.co/Fxgiu6D72j https://t.co/b8dMCOC18F
Dr. John Cush RheumNow ( View Tweet)
GLP-1 Inhibitor Reduces Knee Osteoarthritis Pain
Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis, a randomized trial showed.
https://t.co/Ch5XYlq6lX
Dr. John Cush RheumNow ( View Tweet)
Medscape 2024 Medical Student Experience Survey
Medscape has published a survey overview of US Medical Student impressions and experiences, satisfaction, what they think of their education and how prepared are they for the USMLE (boards) and residency.
https://t.co/WARsNeV3kJ https://t.co/Jaxw0CDsHD
Dr. John Cush RheumNow ( View Tweet)
EUSTAR study, 257 PSS pts. w/ 12+ mos F/U, skin Dz was 70% stable, 22% regressive, 7% progressive. Regressive skin change pts had significantly lower probability of FVC decline ≥10% & all-cause mortality (p=0.035) vs progressive patients https://t.co/3L9iVTPwKv https://t.co/NMuD8VW7Pu
Dr. John Cush RheumNow ( View Tweet)
Are seronegative RA and clinically suspect arthralgia pts represented in randomized clinical trials? Most RCTs (And prevention trials) predominantly enroll seropositive patients. - potentially overlooking seronegative individuals with arthralgia-at-risk. https://t.co/D1eOApgn1p https://t.co/IBCNtNW8uI
Dr. John Cush RheumNow ( View Tweet)
How would you treat an anti-synthetase overlap pt w/ myositis, polysynovitis & rapid ILD (pt on steroids)?
Dr. John Cush RheumNow ( View Tweet)
Filgotinib Efficacy and Safety - 3 Years Later
Filgotinib, the rheumatoid arthritis (RA) oral drug that never made it to the U.S. market but is sold across Europe, Great Britain, and Japan, remained effective for 3 years for most registration trial participants who continued in… https://t.co/eABIG1Kal6 https://t.co/7ZphZALniE
Dr. John Cush RheumNow ( View Tweet)
Treatment Options for Dupuytren’s Contracture
The NEJM reports that in a randomized, controlled, head to head trial, collagenase injections were non-inferior to limited fasciectomy in the treatment of Dupuytren’s contracture.
https://t.co/HTW9za8a10 https://t.co/gStCic7x2D
Dr. John Cush RheumNow ( View Tweet)
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis https://t.co/luhFvy3yjR https://t.co/52oiTYG3a4
Dr. John Cush RheumNow ( View Tweet)